The historical rank and industry rank for Aarti Pharmalabs's FCF Margin % or its related term are showing as below:
NSE:AARTIPHARM'
s FCF Margin % Range Over the Past 10 Years
Min: -15.51 Med: -5.38 Max: 6.74
Current: -10.24
During the past 6 years, the highest FCF Margin % of Aarti Pharmalabs was 6.74%. The lowest was -15.51%. And the median was -5.38%.
NSE:AARTIPHARM's FCF Margin % is ranked worse than 74.11% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs NSE:AARTIPHARM: -10.24
Aarti Pharmalabs FCF Margin % Related Terms
Aarti Pharmalabs FCF Margin % Historical Data
* Premium members only.
The historical data trend for Aarti Pharmalabs's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Pharmalabs FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Aarti Pharmalabs's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Pharmalabs (NSE:AARTIPHARM) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aarti Pharmalabs and its competitors. According to the industry distribution chart, Aarti Pharmalabs ranks #710 out of 958 companies in the Drug Manufacturers industry, placing it in the top 74.1%.
Is Aarti Pharmalabs' FCF Margin % too high?
Aarti Pharmalabs' current FCF Margin % is 0.00%. Based on the distribution chart, Aarti Pharmalabs ranks #710 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aarti Pharmalabs has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Pharmalabs ranks #710 out of 958 companies for FCF Margin %. This places Aarti Pharmalabs in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aarti Pharmalabs and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Pharmalabs's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹636.14, compared to a current price of ₹690.70 — trading 8.6% above its estimated fair value. The current FCF Margin % is 0.00%. Aarti Pharmalabs' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued.
The current stock price of ₹690.70 is trading 8.6% above its estimated GF Value™ of ₹636.14.
GuruFocus considers Aarti Pharmalabs to be Fairly Valued.
Key valuation signals for NSE:AARTIPHARM:
FCF Margin %: 0.00%
GF Value™: ₹636.14 vs. price of ₹690.70 (8.6% above fair value)
No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
56GF Score
Get the complete analysis for NSE:AARTIPHARM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIPHARM has been successfully added to your 
